anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mycophenolate sodium (Myfortic®) is an antiproliferative immunosuppressant used in renal transplantation. Mycophenolate sodium is formulated as an enteric coated tablet that releases mycophenolic acid (MPA) which in turn inhibits inosine monophosphate dehydrogenase (IMPDH). Through inhibition of IMPDH, the de novo pathway of purine synthesis, which T and B lymphocytes rely on for proliferation, is blocked. The pharmacokinetic profile of mycophenolate sodium has mainly been studied in combination with cyclosporine and steroids. There is little information on the pharmacokinetics of mycophenolate sodium in combination with tacrolimus and currently no published information in steroid withdrawal. All current published data on the pharmacokinetics of MPA have been in patients receiving chronic corticosteroids as part of their immunosuppression regimen. As immunosuppression minimization, and especially corticosteroid withdrawal, become more popular it is important to understand how mycophenolate sodium and its metabolites behave in a two-drug maintenance immunosuppression regimen. The study will assess the pharmacokinetic profile of mycophenolate sodium in patients on tacrolimus dose adjusted based on levels, and a steroid withdrawal protocol.

Renal transplant patients will act as their own controls in a randomized crossover design with pharmacokinetic profiles occurring at two different time points. Immunosuppression will consist of induction therapy with maintenance immunosuppression consisting of tacrolimus plus mycophenolate sodium. Corticosteroids will be withdrawn per institutional protocol within the first week post transplant.

Approximately 3-4 weeks post transplant, patients that met enrollment criteria and have consented to participate in the study will be instructed to take 720 milligrams of mycophenolate sodium orally twice daily for one week either separated from food by two hours (fasting state) or with a meal (fed state). After one week, patients will be admitted for approximately 24 hours where they will continue to receive mycophenolate sodium with or without food. During this period, blood samples will be drawn at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours following the dose to evaluate levels of mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG). After 24 hours, patients will be discharged with instructions to take mycophenolate sodium in the opposite manner (fed or fasting state) than they had the week before. At the end of the second week the patients will return for a second PK evaluation with blood collection at the same time points following mycophenolate sodium dosing.
Memory impairment affects cognition and information processing, and attention, leading to a decline in life quality of patients. Previous studies have shown the memory-improving effects of sea cucumber peptides. This study further explored the memory-improving mechanisms of sea cucumber peptides using scopolamine-induced memory-impaired mice and identified novel memory-improving peptides within low molecular weight peptide fractions. The sea cucumber peptides were categorized into three groups based on their molecular weights: SCP-L (molecular weight greater than 10 kDa), SCP-M (weight between 3 kDa and 10 kDa), and SCP-S (molecular weight less than 3 kDa). The results showed that SCP-S improved behavioral performance by regulating cholinergic system disorder and reducing oxidative stress levels, distinguishing itself from SCP-M and SCP-L. Further, SCP-S was found to exhibit a well ability in alleviating the degree of neuroinflammation dependent on microglia and promoting synaptic plasticity. Additionally, a novel memory-improving peptide Ser-Phe-Gly-Asp-Ile (SFGDI) was identified by EASY-nano-LC/MS/MS after simulated digestion-absorption coupling of in silico technologies from SCP-S. SFGDI protected against oxidative stress and regulated cholinergic system in scopolamine-induced PC12 cells. These findings suggest that SCP-S and SFGDI might be considered as potential memory-improving food for people suffering from memory disorders.
Participants will be asked to continue whatever they are already doing to care for their back pain. Length of the usual care condition will be 5 weeks, the expected mean completion time of the PRT and CBT arms, and may be adjusted at mid-enrollment to match treatment arm length more closely.
A repellent for agricultural crops that uses accepted all natural components to protect crops organically. The repellent uses a combination of red pepper, powdered, garlic and black pepper to repel undesirable pests. Hydrated calcium hydroxide is added to the combination to increase the stability of the resultant mixture. The calcium hydroxide also acts as a fertilizer on some soils by increasing soil pH. The peppers contain alkaloids that yield nitrogen when decomposed fully. The repellent comprises, by weight percentage, between 3% and 20% red pepper, between 3% and 20% powdered garlic, between 3% and 20% black pepper, and between 40% and 91% hydrated calcium hydroxide. Preferably, the repellent comprises 10.7% red pepper, 10.7% powdered garlic, 10.6 black pepper and 68% hydrated calcium hydroxide. The repellent components are combined and thoroughly blended to produce a mixture that may be applied to any crop to prevent most pest infestations. The mixture may be applied with known conventional applicators, including aerial crop dusters. The mixture does not harm plants and/or people and/or livestock at practical application rates. Therefore, potential damage to adjacent crops and/or areas is minimized when aerially applying the mixture.
With the availability of BCR::ABL1 targeted tyrosine kinase inhibitors (TKIs), outcomes for most individuals with chronic phase chronic myeloid leukemia (CP-CML) are outstanding, with life expectancy similar to age-matched peers. Treatment-emergent adverse events (TEAEs) impair quality of life and many patients struggle with low-level chronic AEs, which for some individuals impact emotional well-being as well as social and work functioning. An emerging body of data supports that many TEAEs are related to therapy dose and can improve with dose reduction. However, it is critical that dose reductions do not alter current outcomes, especially in the rare patients who are at greater risk of losing response or transforming to acute leukemia. Organizations including the National Comprehensive Cancer Network have begun to address when dose reductions may be considered in patients with CP-CML. In this manuscript, we review retrospective and prospective data reporting outcomes in patients after dose reduction and review data supporting lower dose preemptive dosing in first-line and later-line therapy. Switching therapy for intolerance can result in improvements in symptoms and limit toxicity, but other TEAEs may occur. Additionally, emerging therapeutics such as the new class of BCR::ABL1 allosteric inhibitors are under evaluation with a goal of improving tolerability. However, with many TKIs on the cusp of becoming generic, dose reduction becomes an appealing and important cost-effective strategy to minimize TEAEs and improve quality of life while preserving outstanding outcomes in CP-CML.
Provided herein are substituted furanyl compounds, e.g., compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate eIF4E activity. In one embodiment, the compounds provided herein modulate the Hedgehog pathway activity. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders. (see formula I)
Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin prep over the suspected skin incision site for 30 sec - the first applicator will then be used in a back and forth pattern work up towards the upper edge of the surgical field. The first applicator will then be discarded. The second applicator will then again start at the expected site of the incision and again working inferiority until the lower edge of the surgical field is reached.
Photobiomodulation (PBM) has attracted widespread attention in suppressing various pain and inflammation. Primary dysmenorrhea (PD) primarily occurs in adolescents and adult females, and the limited effectiveness and side effects of conventional treatments have highlighted the urgent need to develop and identify new adjunct therapeutic strategies. In this work, the results of pain and PGs demonstrated that 850 nm, 630 nm, and 460 nm all exhibited pain inhibition, decreased PGF2α and upregulated PGE2, while 630 nm PBM has better effectiveness. Then to explore the underlying biological mechanisms of red light PBM on PD, we irradiated prostaglandin-F2α induced HUSM cells and found that low-level irradiance can restore intracellular calcium ion, ROS, ATP, and MMP levels to normal levels. And, red light enhanced cell viability and promoted cell proliferation for normal HUSM cells. Therefore, this study proposes that red light PBM may be a promising approach for the future clinical treatment of PD.
On average, deaf and hard-of-hearing (DHH) children have difficulty developing expressive spoken vocabulary comparable to hearing peers. Yet, there are no evidence-based practices to guide classroom instruction for teachers of the deaf. Retrieval practice-a robust learning strategy-has been shown to improve children's retention of vocabulary, but it has not been investigated with DHH children who use listening and spoken language. The present study examined whether DHH children benefit from using retrieval practice to learn new vocabulary. Sixteen DHH children (in the age range of 5.0-8.11 years) were taught a set of new vocabulary words using retrieval practice or repeated exposure. A recall test was administered two days later. Results showed that DHH children were twice as likely to recall a word taught through retrieval practice than exposure (OR = 2.01, p = .02). Presence of an additional diagnosis and number of practice trials were also significant predicting factors of vocabulary learning.
The onset of sarcopenia is intimately linked with aging, posing significant implications not only for individual patient quality of life but also for the broader societal healthcare framework. Early and accurate identification of sarcopenia and a comprehensive understanding of its mechanistic underpinnings and therapeutic targets paramount to addressing this condition effectively. This review endeavors to present a cohesive overview of recent advancements in sarcopenia research and diagnosis. We initially delve into the contemporary diagnostic criteria, specifically referencing the European Working Group on Sarcopenia in Older People (EWGSOP) 2 and Asian Working Group on Sarcopenia (AWGS) 2019 benchmarks. Additionally, we elucidate comprehensive assessment techniques for muscle strength, quantity, and physical performance, highlighting tools such as grip strength, chair stand test, dual-energy X-ray Absorptiometry (DEXA), bioelectrical impedance analysis (BIA), gait speed, and short physical performance battery (SPPB), while also discussing their inherent advantages and limitations. Such diagnostic advancements pave the way for early identification and unequivocal diagnosis of sarcopenia. Proceeding further, we provide a deep-dive into sarcopenia's pathogenesis, offering a thorough examination of associated signaling pathways like the Myostatin, AMP-activated protein kinase (AMPK), insulin/IGF-1 Signaling (IIS), and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways. Each pathway's role in sarcopenia mediation is detailed, underscoring potential therapeutic target avenues. From a mechanistic perspective, the review also underscores the pivotal role of mitochondrial dysfunction in sarcopenia, emphasizing elements such as mitochondrial oxidative overload, mitochondrial biogenesis, and mitophagy, and highlighting their therapeutic significance. At last, we capture recent strides made in sarcopenia treatment, ranging from nutritional and exercise interventions to potential pharmacological and supplementation strategies. In sum, this review meticulously synthesizes the latest scientific developments in sarcopenia, aiming to enhance diagnostic precision in clinical practice and provide comprehensive insights into refined mechanistic targets and innovative therapeutic interventions, ultimately contributing to optimized patient care and advancements in the field.
The utility model belongs to the technical field of chronic disease monitoring system, especially, be a chronic disease monitoring system based on internet, including doctor's workstation, doctor's workstation is connected with the router No. one through the net twine, the router has a hot wall through the net twine connection, No. one hot wall connection has the HIS server, the HIS server is connected with the HIS database, No. one hot wall has network operator through optical fiber connection, network operator's route table is connected with No. two hot walls and No. three hot walls of preventing respectively, No. two hot walls of preventing are connected with No. two routers. The utility model discloses an establish the chronic disease monitoring system based on public health platform, the information degree of the chronic disease monitoring management work in my market has obtained the improvement of very big degree, and the time that the mechanism of disease control acquireed chronic disease monitoring information shortens greatly, and personnel's work burden is alleviateed, and work efficiency and accuracy all obtain improving by a wide margin.
Subjects will have TruGraf and TRAC testing at study enrollment (Baseline) and thereafter every 3 months. In addition subjects will have TRAC testing at any time there is a suspicion of acute rejection.
The primary objective of this study was to investigate the etiological causes and the underlying mechanism of post-earthquake dizziness in affected persons. The present study utilized an observational case-control design to recruit 69 participants (33 with self-reported dizziness complaints and 36 healthy persons) who were exposed to the 2023 earthquakes in Türkiye. The participants underwent assessments including the Dizziness Handicap Inventory for measuring dizziness-related disability, stress, and anxiety assessment using various scales, and equilibrium evaluation through the use of videonystagmography, video head impulse test, and vestibular evoked myogenic potential. The 2 groups were compared based on these assessments. The results indicate that the Dizziness Handicap Inventory score was significantly higher in the patient group compared to the control group (P < .001). The mean score of the Peritraumatic Distress Inventory, as well as the mean scores of the Hospital Anxiety and Depression Scale anxiety score and depression score, were found to be significantly higher in the patient group compared to the control group (P=.012, P < .001, and P < .001, respectively). Furthermore, it was observed that the mean vestibulo-ocular reflex gain of the left posterior semicircular canal exhibited a statistically significant decrease in the patient group (P=.02). The observed equilibrium dysfunction experienced by individuals following a significant earthquake is likely attributable to heightened stress and anxiety stemming from multiple sources, including the impact of recurrent vibrations on the inner ear. Therefore, it is essential to establish a holistic healthcare approach that addresses the psychological needs of individuals affected by earthquakes.
Hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics) [see Drug Interactions (7)].  Monitor these patients for signs of hypotension after initiating or titrating the dosage of hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets. In patients with circulatory shock, hydromorphone hydrochloride may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets in patients with circulatory shock.
Amputation secondary to vascular complications of recurrent dislocations after total hip arthroplasty (THA) is an extremely rare. We describe an unusual case of above-knee amputation resulting from vascular complications after recurrent dislocations of a THA. A 63-year-old male patient with walking pain and limp has a history of acetabular fracture and central dislocation of the femoral head. He was diagnosed as post-traumatic arthritis and subluxation of the femoral head and suffered from four similar dislocations in 210 days after the THA. The patient received conservative treatment after every hip dislocation. However, four months after the fourth reduction, the emergent femoral artery and popliteal artery exploration and catheter thrombectomy were performed at another hospital. An ipsilateral above-knee amputation was done after sepsis and failure of the revascularization procedure. Clinicians should be cognizant that above-knee amputation resulting from vascular complications after recurrent dislocations of a THA may occur. The lack of adherence to critical treatment may have led to the severe outcome of amputation. In conclusion, patient education and compliance are essential for both the treatment of hip dislocations and arterial occlusion. More active and effective measures should be used to prevent such catastrophic events.
The initial hu14.18-IL2 fusion protein (FP) dose will be 2 mg/m2 given intravenously over 4 hours, daily for 3 days. Five separate dose levels are scheduled: 2 mg/m²/dose (IV over 4 hours) x 3 days, 4 mg/m²/dose (IV over 4 hours) x 3 days, 6 mg/m²/dose (IV over 4 hours) x 3 days, 8 mg/m²/dose (IV over 4 hours) x 3 days, 10 mg/m²/dose (IV over 4 hours) x 3 days.
PROBLEM TO BE SOLVED: To obtain a film-coated granule having a controlled dissolution rate of a medicine, excellent in stability of dissolution rate with time, by coating the outside of a spherical raw granule containing a medicine with a medicine dissolution rate adjusting film having a proper strength. SOLUTION: A spherical raw granule containing a medicine is coated with a film coating agent which is a water dispersion comprising a spherical solid particle consisting essentially of ethyl cellulose and having substantially <=1μm diameter, a plasticizer and a medicine dissolution rate adjusting substance and forms a film having >=0.08kgf strength to give the objective film-coated granule. The spherical granule containing the medicine preferably comprises a medicine and a spherical nuclear particle and the nuclear particle contains preferably >=30wt.% crystalline cellulose. Hydroxypropyl cellulose and hydroxypropyl cellulose are preferable as the medicine dissolution rate adjusting substance. The content of the substance is 15-35wt.% in the film. The thickness of the film is preferably >=30μm.
The present invention relates to a mask pack that enables a lifting massage of a jaw line using a massage tool even while wearing the mask pack. The mask pack includes a sheet body in which a skin improving agent is impregnated so that the sheet body can be attached to a jaw area of a user′s face. The sheet body is formed with a size smaller than a size of a contour of the user′s face and has elasticity so that the sheet body extends in the longitudinal direction. The sheet body is formed at both side ends thereof with earring portions, thus, when the sheet body is attached to the user′s face, the sheet body is deformed along the user′s face so that both jaw portions of the user are lifted upward by elasticity. Through holes are formed toward the earring portions and symmetrically arranged in left and right directions about the sheet body. The through holes extend close to the jaw line and are opened when the user wears the mask pack so that it is possible to simultaneously perform a lifting massage using a massage tool through the exposed skin. In addition, the through holes are divided into an upper through hole and a lower through hole by a partition portion such that the through holes extend in a state in which the through holes are located in the jaw line of the user so as to lift a cheek skin formed at the top of the jaw line and a jaw skin formed at the bottom of the jaw line. The through holes are symmetrical to each other about the center in the left and right directions and have a rectangular shape extending in the longitudinal direction while being inclined horizontally or upwardly inclined toward the earring portions. Thus, the through holes may serve as a guide when performing massage on upper and lower sides of the jaw line by using the massage tool.
The invention discloses a biological guidance oncolytic virus preparation and application, wherein the virus is a recombinant Newcastle disease oncolytic virus containing a recombinant NDV-EPGPF plasmid, and the recombinant Newcastle disease oncolytic virus is obtained by rescuing BSR cells through cotransfection of the recombinant NDV-EPGPF plasmid and a helper plasmid. The recombinant NDV-EPGPF plasmid is an NDV plasmid comprising recombinant α 1,3GT, CD105scFv, PD-1scFv, PD-L1 scFv and FAP scFv genes; the sequence of the CD105scFv gene is shown as SEQ ID NO. 1; the sequence of the PD-1scFv gene is shown as SEQ ID NO. 2; the sequence of the alpha-1, 3GT gene is shown in SEQ ID NO 3; the sequence of the PD-L1 scFv gene is shown as SEQ ID NO. 4; the sequence of the FAP scFv gene is shown as SEQ ID NO. 5. The invention also discloses a preparation method of the recombinant Newcastle disease oncolytic virus and application of the recombinant Newcastle disease oncolytic virus in intravenous injection for resisting tumor, destroying a tumor skeleton structure and activating T cell function.
PURPOSE: To obtain a vaccine, comprising an antigenic immobilized liposome in which an antigen is immobilized only on the outer aqueous phase side of a liposome and capable of suppressing the production of IgE by the priming and increasing the production of IgG and thereby hardly causing allergic diseases and excellent in safety, stability, etc. CONSTITUTION: This antigen bonding liposome type vaccine contains a phospholipid containing amino group (e.g. phosphatidylethanolamine, phosphatidylserine or a phospholipid derived from egg yolk or soybean) as a membrane constituent component. An antigen is immobilized on only the outer aqueous phase side of a liposome having 0.1-3μm, preferably 0.2-2.5μm particle diameter and a saccharide (preferably monosaccharides or disaccharides, especially derivative glucose) is further contained in an inner and outer aqueous phases. The titer ratio of the production amount of IgG to that of IgE is preferably 100-10,000. The concentration of the saccharide contained in the inner and outer aqueous phases is 0.05-0.5M, preferably 0.15-0.35M.